# Adversarial review — microplastics-cardiovascular

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Level before → after: Γ Moderate → Γ Moderate (unchanged).
Findings: 0 Critical, 2 Major, 1 Minor, 0 Editorial. PMIDs verified 59/59. Claims spot-checked: 12. Validator: PASS (0 fail, 0 warn, 30 pass).

| # | Severity | Location | Original → corrected | Evidence |
|---|---|---|---|---|
| 1 | Major | AT A GLANCE, "Best-supported rival" | nominal model named as the rival → rank-1 non-nominal model (disease-related trapping and barrier disruption) | Score card M1 is `is_nominal: true`; renderer printed `models_evaluated[0]`. |
| 2 | Major | Gamma hard-rule audit, SC3 | "Not triggered literally" → "Triggered literally ... recorded for SC3 in the cap audit" | `cap_rules_applied` records the same quoted rule for SC3 as triggered with a Γ ceiling. |
| 3 | Minor | Score card `final_score.confidence_rationale` | access depth cited as a confidence input → rationale rescoped to density, replication and heterogeneity | Framework Confidence band: confidence reflects evidence density and reproducibility, not reviewer access. Band stays Moderate. |

Rejected findings, residual limitations and the approval line are recorded in the review's `## ADVERSARIAL REVIEW AND APPROVAL` section and in `adversarial-findings.json`.

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.